Special Issue "Assessment of Avian Influenza Vaccine: Biochemical Characterization and Genetic Identification of Virus Strains"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 114
Interests: etiology of influenza virus; Influenza-related mechanisms of inflammation; antiviral immunity
Interests: influenza vaccine development; etiology of influenza virus
As you are already aware, influenza viruses are highly prevalent pathogens transmitted by air droplets or direct contact. WHO reported that 290000–650000 deaths are related to influenza each year in the world. Additionally, influenza pandemics are still a concern to human besides seasonal influenza. In the last hundred years, four influenza A virus pandemics have had a devastating effect. Studies of virus traceability have demonstrated that avian influenza virus or genes of avian influenza virus were believed to contribute to all four pandemic viruses. Sporadic human cases with avian influenza infection and influenza outbreak in poultry or wildfowl were reported frequently by multiple countries in the world. Avian influenza viruses would not be ignored in concern of next influenza pandemic. At present, vaccination was believed to be the most effective way on prevention and control of influenza. However, a major difficulty in the development of pre-pandemic vaccines is to identify which zoonotic virus may cause the next pandemic. To promote the technological preparedness or theoretical recognition on potential influence pandemic, we are launching a Special Issue entitled “Assessment of Avian Influenza Vaccine: Biological Characterization and Genetic Identification of Virus Strains”. This Special Issue will include high-quality papers on topics within the broad scope of Vaccines. We will consider manuscripts that investigate anti-viral and anti-influenza immunity, immunological responses to potential viral vaccine antigens, the testing of viral vaccine candidates in animals and humans, the delivery methods of viral vaccine antigens, studies on vaccine adjuvants related to viral vaccine development, investigations of viral vaccine strategies that aim to raise broadly neutralizing antibodies, and theoretical studies that suggest and rationalize novel types of viral vaccines or novel ways of stimulating protective anti-viral immunity.
Dr. Rongbao Gao
Dr. Li Xin
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- avian influenza
- antiviral immunity